The outcome of clinical trials can make or break biotech stocks. The following are some of the anticipated near-term clinical trial data readouts worth keeping an eye on.
Annovis Bio Inc. (ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is awaiting topline data from a phase III study of its lead drug candidate Buntanetap in patients with early Parkinson's disease.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com